TRT Risks, Honestly

Every working medicine has a risk ledger, and testosterone's is better documented than most — not because it is dangerous, but because a 2010 trial that went wrong forced the field to count. This page walks the ledger straight: the cardiovascular signals from the halted TOM trial through TRAVERSE, the fertility suppression almost no advertisement mentions, the thickening blood that shows up in routine labs, and the monitoring schedule that keeps all of it manageable.

The Risk Ledger, Read Straight

Testosterone's adverse-event profile is dominated by predictable pharmacology rather than surprises: it builds red cells, feeds the prostate's metabolism, suppresses the brain's signal to the testes, and can worsen sleep-disordered breathing. None of these is unknown; all of them are monitorable. The table below is the working ledger — every row is a reason the prescription comes with lab slips, and none of them is a reason to panic if the monitoring happens. The parent topic's risk table summarizes; this page counts.

The Cardiovascular Story, Start to Finish

The cardiovascular question has three chapters, and they must be read in order. Chapter one, 2013: two observational studies reported higher rates of heart attack and stroke in men prescribed testosterone (Vigen et al., JAMA, 2013, and a claims-based companion) — analyses criticized for statistical handling that may have reversed the finding, but the alarm was raised, and prescriptions fell. Chapter two, 2010–2016: the TOM trial — 209 men, mean age 74, with mobility limitations and heavy comorbidity, randomized to testosterone gel or placebo — was stopped by its monitoring board when cardiovascular-related adverse events stacked up 23 to 5 against the treated arm (Basaria et al., NEJM, 2010). The lesson was not "the hormone is toxic"; it was "dose escalation in a frail, high-risk population without monitoring is how you get hurt." Chapter three, 2023: TRAVERSE answered the question the right way, in the right population, and the answer was the one covered on the trials page: major cardiac events non-inferior to placebo over roughly two years, with small directional signals for fibrillation, kidney injury, and embolism, and an individual-patient meta-analysis pointing the same direction (Hudson et al., Lancet Healthy Longevity, 2022). The honest synthesis: short-term cardiovascular safety in properly monitored, genuinely hypogonadal men is now better documented than for most hormone therapies — and the chapter beyond year three is unwritten. For the broader context of male cardiovascular risk, see the men's cardiovascular topic.

Fertility: The Trade-Off Most Marketing Omits

Exogenous testosterone tells the pituitary to stop signaling the testes, and the testes — no longer asked to work — wind down sperm production. Most men on replacement therapy become markedly oligospermic or azoospermic within months; this is not a side effect so much as the mechanism working as designed. The recovery data come from hormonal male contraception studies, where suppression was the goal: across 1,549 healthy young men, the median time for sperm concentration to recover to a fertile threshold after stopping was 3.4 months, and cumulative recovery reached roughly two-thirds by six months, 90 percent by twelve, and essentially all by twenty-four (Liu et al., Lancet, 2006). Note the caveats: those were young, healthy, eugonadal men using shorter-acting regimens — not necessarily the older therapeutic population — and "essentially all" is still not "everyone, without exception." A man who wants children in the next several years is in a different calculus entirely, and specialist co-therapy (gonadotropin support) is a real option rather than an afterthought.

The Monitoring Schedule, Actually

The Endocrine Society's guideline turns the risk ledger into a schedule, and the schedule is what makes the ledger livable (Bhasin et al., JCEM, 2018). The shape, in plain terms: before starting — symptom history, two confirmatory morning draws, baseline hematocrit, and prostate assessment (PSA on the standard screening logic); then a check at three to six months, again at twelve, and annually thereafter, with hematocrit and testosterone levels at each visit and dose adjustment to keep levels in the mid-normal range rather than "higher is better." Hematocrit climbing past the action threshold — conventionally 54 percent — triggers dose reduction or a pause, which is why polycythemia tops the "most common" list but rarely tops the "most harmful" one: it is found on routine labs before it finds you. The red flags that should not wait for the annual visit are in the box below.

Questions, Answered Briefly

• 🫀 Is TRT going to give me a heart attack? The best evidence says no increase in major cardiac events over roughly two years in properly selected men — with small directional signals elsewhere that monitoring exists to catch.
• 🩸 Why does my blood "thicken," and does it matter? Testosterone stimulates red-cell production; hematocrit above the action threshold raises clotting risk, which is exactly why the lab schedule includes it and why it rarely becomes clinical.
• 👶 I want children eventually. Is TRT off the table? Not automatically — but it changes the conversation: expect suppression while on therapy, plan the timeline with a specialist, and know that recovery after stopping is typical but not certain.
• 😴 I snore. Can I still consider therapy? Undiagnosed or untreated apnea should be addressed first — therapy can worsen it, and apnea itself suppresses testosterone, so treating the apnea sometimes solves part of the original problem.
• 🔍 Does TRT cause prostate cancer? No short-term signal — TRAVERSE showed numerically fewer cases in the treated arm, which the authors said not to over-read. The honest position: monitored with PSA, long term unknown.

Related Topics